|
Kalos Therapeutics is a biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer.〔(Business Week Article )〕 Kalos has been covered by ABC News 〔(GMA )〕 on Good Morning America, and profiled in Business Week〔(ABC News )〕 and Time Magazine.〔(Time Magazine )〕 The company aggressively targets diseases caused by an abnormally high growth rate of cells (hyper proliferation),〔(Drugs.com Article )〕 and is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.〔(Kalos website )〕 KT-220, the current lead drug candidate, demonstrates remarkably broad anti-cancer activity. KT-220 has inhibited the growth of pancreatic, lung, prostate, breast, ovarian, colon, and melanoma cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer.〔(Drugs.com Article )〕 ==Board Members== George Colberg - Chairman & CEO James Merritt, M.D. - President and Chief Medical Officer Gregory F. Witchel, MBA - Executive Vice President Daniel Von Hoff, MD, FACP - Chairman, Scientific Advisory Board David L. Vesely, MD, PhD - Scientific Advisory Board Marc B. Garnick, MD - Scientific Advisory Board Patrice P Rioux, MD, PhD - Scientific Advisory Board Derek E Vest - Secretary 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Kalos Therapeutics」の詳細全文を読む スポンサード リンク
|